A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells

ACS Chemical Biology

Volumn 11, Issue 4, 2016, Pages 921-930

  Matheson, Christopher J ^a   Venkataraman, Sujatha ^b   Amani, Vladimir ^b   Harris, Peter S ^b   Backos, Donald S ^a   Donson, Andrew M ^b   Wempe, Michael F ^a   Foreman, Nicholas K ^b   Vibhakar, Rajeev ^b   Reigan, Philip ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; CISPLATIN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; WEE1 PROTEIN, HUMAN;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; DRUG POTENTIATION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; HUMANS; MEDULLOBLASTOMA; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84966376866     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00725     Document Type: Article

References (48)

1. Packer, R. J., Cogen, P., Vezina, G., and Rorke, L. B. (1999) Medulloblastoma: clinical and biologic aspects Neuro Oncol 1, 232-250 10.1093/neuonc/1.3.232
2. Pizer, B. L. and Clifford, S. C. (2009) The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials British journal of neurosurgery 23, 364-375 10.1080/02688690903121807
3. Packer, R. J. (2005) Progress and challenges in childhood brain tumors J. Neuro-Oncol. 75, 239-242 10.1007/s11060-005-6745-9
4. O'Leary, M., Krailo, M., Anderson, J. R., and Reaman, G. H. (2008) Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group Semin. Oncol. 35, 484-493 10.1053/j.seminoncol.2008.07.008
5. Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., and Boyett, J. M. (2001) Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study J. Clin. Oncol. 19, 3470-3476
6. Mulhern, R. K., Palmer, S. L., Merchant, T. E., Wallace, D., Kocak, M., Brouwers, P., Krull, K., Chintagumpala, M., Stargatt, R., Ashley, D. M., Tyc, V. L., Kun, L., Boyett, J., and Gajjar, A. (2005) Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma J. Clin. Oncol. 23, 5511-5519 10.1200/JCO.2005.00.703
7. Packer, R. J., Cogen, P., Vezina, G., and Rorke, L. B. (1999) Medulloblastoma: clinical and biologic aspects Neuro-oncol 1, 232-250 10.1093/neuonc/1.3.232
8. Jennings, M. T., Cmelak, A., Johnson, M. D., Moots, P. L., Pais, R., and Shyr, Y. (2004) Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy Pediatr. Blood Cancer 43, 46-54 10.1002/pbc.20043
9. Koberle, B., Tomicic, M. T., Usanova, S., and Kaina, B. (2010) Cisplatin resistance: preclinical findings and clinical implications Biochim. Biophys. Acta, Rev. Cancer 1806, 172-182 10.1016/j.bbcan.2010.07.004
10. Newton, H. B. (2001) Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma Expert Opin. Invest. Drugs 10, 2089-2104 10.1517/13543784.10.12.2089
11. Onoyama, Y., Abe, M., Takahashi, M., Yabumoto, E., and Sakamoto, T. (1975) Radiation therapy of brain tumors in children Radiology 115, 687-693 10.1148/15.3.687
12. Knight, K. R., Kraemer, D. F., and Neuwelt, E. A. (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development J. Clin. Oncol. 23, 8588-8596 10.1200/JCO.2004.00.5355
13. Paulino, A. C., Lobo, M., Teh, B. S., Okcu, M. F., South, M., Butler, E. B., Su, J., and Chintagumpala, M. (2010) Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma Int. J. Radiat. Oncol., Biol., Phys. 78, 1445-1450 10.1016/j.ijrobp.2009.09.031
14. Lafay-Cousin, L., Purdy, E., Huang, A., Cushing, S. L., Papaioannou, V., Nettel-Aguirre, A., and Bouffet, E. (2013) Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma Pediatr Blood Cancer. 60, 287 10.1002/pbc.24307
15. Chou, Y. T., Liao, P. W., Lin, M. C., Chou, J. C., Lin, Y. H., Lin, M. H., Tang, S. H., and Chen, M. H. (2011) Medulloblastoma presenting with pure word deafness: report of one case and review of literature Pediatrics and neonatology 52, 290-293 10.1016/j.pedneo.2011.06.009
16. Harris, P. S., Venkataraman, S., Alimova, I., Birks, D. K., Balakrishnan, I., Cristiano, B., Donson, A. M., Dubuc, A. M., Taylor, M. D., Foreman, N. K., Reigan, P., and Vibhakar, R. (2014) Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma Mol. Cancer 13, 72 10.1186/1476-4598-13-72
17. Chen, T., Stephens, P. A., Middleton, F. K., and Curtin, N. J. (2012) Targeting the S and G2 checkpoint to treat cancer Drug Discovery Today 17, 194-202 10.1016/j.drudis.2011.12.009
18. Bucher, N. and Britten, C. D. (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br. J. Cancer 98, 523-528 10.1038/sj.bjc.6604208
19. Do, K., Doroshow, J. H., and Kummar, S. (2013) Wee1 kinase as a target for cancer therapy Cell Cycle 12, 3348 10.4161/cc.26062
20. Indovina, P. and Giordano, A. (2010) Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs Cancer Biol. Ther. 9, 523-525 10.4161/cbt.9.7.11276
21. Jin, P., Gu, Y., and Morgan, D. O. (1996) Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells J. Cell Biol. 134, 963-970 10.1083/jcb.134.4.963
22. Igarashi, M., Nagata, A., Jinno, S., Suto, K., and Okayama, H. (1991) Wee1(+)-like gene in human cells Nature 353, 80-83 10.1038/353080a0
23. McGowan, C. H. and Russell, P. (1993) Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15 EMBO J. 12, 75-85
24. Parker, L. L. and Piwnica-Worms, H. (1992) Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase Science 257, 1955-1957 10.1126/science.1384126
25. De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J., and Wurdinger, T. (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe Clin. Cancer Res. 17, 4200-4207 10.1158/1078-0432.CCR-10-2537
26. Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., Itadani, H., Takahashi-Suzuki, I., Fukasawa, K., Oki, H., Nambu, T., Jiang, J., Sakai, T., Arakawa, H., Sakamoto, T., Sagara, T., Yoshizumi, T., Mizuarai, S., and Kotani, H. (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Mol. Cancer Ther. 8, 2992-3000 10.1158/1535-7163.MCT-09-0463
27. Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., Mizuarai, S., Iwasawa, Y., and Kotani, H. (2010) MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil Cancer Biol. Ther. 9, 514-522 10.4161/cbt.9.7.11115
28. Indovina, P. and Giordano, A. (2010) Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs Cancer Biol. Ther. 9, 523-525 10.4161/cbt.9.7.11276
29. Leijen, S., Beijnen, J. H., and Schellens, J. H. (2010) Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents Curr. Clin. Pharmacol. 5, 186-191 10.2174/157488410791498824
30. Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A., Zwinderman, A. H., Geerts, D., Kaspers, G. J., Peter Vandertop, W., Cloos, J., Tannous, B. A., Wesseling, P., Aten, J. A., Noske, D. P., Van Noorden, C. J., and Wurdinger, T. (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma Cancer Cell 18, 244-257 10.1016/j.ccr.2010.08.011
31. Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., and Meyn, R. E. (2011) MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells Clin. Cancer Res. 17, 5638-5648 10.1158/1078-0432.CCR-11-0650
32. Dillon, M. T., Good, J. S., and Harrington, K. J. (2014) Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of Radiotherapy Clinical Oncology 26, 257-265 10.1016/j.clon.2014.01.009
33. Sakamoto, T., Sunami, S., Yamamoto, F., Niiyama, K., Bamba, M., Takahashi, K., Furuyama, H., Sagara, T., Otsuki, S., Nishibata, T., Yoshizumi, T., and Hirai, H. Dihydropyrazolopyrimidinone Derivatives. WO/2007/126128, 2007
34. Donson, A. M., Weil, M. D., and Foreman, N. K. (1999) Tamoxifen radiosensitization in human glioblastoma cell lines J. Neurosurg. 90, 533-536 10.3171/jns.1999.90.3.0533
35. Metz, J. T., Johnson, E. F., Soni, N. B., Merta, P. J., Kifle, L., and Hajduk, P. J. (2011) Navigating the kinome Nat. Chem. Biol. 7, 200-202 10.1038/nchembio.530
36. Bucher, N. and Britten, C. D. (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br. J. Cancer 98, 523-528 10.1038/sj.bjc.6604208
37. Castedo, M., Perfettini, J. L., Roumier, T., Andreau, K., Medema, R., and Kroemer, G. (2004) Cell death by mitotic catastrophe: a molecular definition Oncogene 23, 2825-2837 10.1038/sj.onc.1207528
38. Kawabe, T. (2004) G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther 3, 513-519
39. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network Nature 408, 307-310 10.1038/35042675
40. Zhou, B. B. and Bartek, J. (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection Nat. Rev. Cancer 4, 216-225 10.1038/nrc1296
41. Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., and Kummar, S. (2015) Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors J. Clin. Oncol. 33, 3409 10.1200/JCO.2014.60.4009
42. Leijen, S., Schellens, J. H., Shapiro, G., Pavlick, A. C., Tibes, R., Demuth, T., Viscusi, J., Cheng, J. D., Xu, Y., and Oza, A. M. (2010) A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors ASCO Meeting Abstracts 28, 3067
43. Pokorny, J. L., Calligaris, D., Gupta, S. K., Iyekegbe, D. O., Jr., Mueller, D., Bakken, K. K., Carlson, B. L., Schroeder, M. A., Evans, D. L., Lou, Z., Decker, P. A., Eckel-Passow, J. E., Pucci, V., Ma, B., Shumway, S. D., Elmquist, W. F., Agar, N. Y., and Sarkaria, J. N. (2015) The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma Clin. Cancer Res. 21, 1916-1924 10.1158/1078-0432.CCR-14-2588
44. Squire, C. J., Dickson, J. M., Ivanovic, I., and Baker, E. N. (2005) Structure and Inhibition of the Human Cell Cycle Checkpoint Kinase, Wee1A Kinase: An AtypicalTyrosine Kinase with a Key Role in CDK1 Regulation Structure 13, 541-550 10.1016/j.str.2004.12.017
45. Beckstein, O., Fourrier, A., and Iorga, B. I. (2014) Prediction of hydration free energies for the SAMPL4 diverse set of compounds using molecular dynamics simulations with the OPLS-AA force field J. Comput.-Aided Mol. Des. 28, 265-276 10.1007/s10822-014-9727-1
46. Bolton, E. E., Wang, Y., Thiessen, P. A., and Bryant, S. H. (2008) Chapter 12-PubChem: Integrated Platform of Small Molecules and Biological Activities, in Annual Reports in Computational Chemistry (Ralph, A. W. and David, C. S., Eds.), pp 217-241, Elsevier.
47. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47, 1739-1749 10.1021/jm0306430
48. Griesinger, A. M., Birks, D. K., Donson, A. M., Amani, V., Hoffman, L. M., Waziri, A., Wang, M., Handler, M. H., and Foreman, N. K. (2013) Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types J. Immunol. 191, 4880-4888 10.4049/jimmunol.1301966